INNOPHARMA has filed an FDA Pre-Submission for FlowStop, a liquid hemostatic spray, and plans a 510(k) for over-the-counter sale. The Daegu company expects to meet with the agency by March 2027 before it files.

FlowStop sold 18,000 human-use units in South Korea between its October 2025 launch and October 2026. Korea's Ministry of Food and Drug Safety certified it as a Class II device in 2025 for local bleeding from stab wounds, lacerations and abrasions. Kaolin in the formula activates the clotting pathway and carboxymethylcellulose holds a gel barrier over the wound. There is no animal-derived chitosan, which matters for shellfish allergy labeling.

In a liver resection animal model at the Daegu-Gyeongbuk Medical Innovation Foundation's preclinical center, bleeding stopped in 2.29 minutes on average with no compression. About 70 percent of subjects stopped within two minutes. A 28-day follow-up reported no inflammation or foreign body reaction. The company cites no human trial data.

An over-the-counter claim raises the bar well past substantial equivalence on the bench. FDA will want human factors work showing an untrained bystander shakes the can long enough and sprays the right wound.